SCHEMBL2494888

SCHEMBL2494888

CCC(CCC(=O)O)N1C(=O)C=CC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 4/20 0.40
PTGS2 P35354 4/20 0.40
CYP1A2 P05177 3/20 0.39
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TP53 P04637 1/20 0.38
GLA P06280 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
ALOX12 P18054 1/20 0.38
NFKB1 P19838 1/20 0.38
APEX1 P27695 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
GABRP O00591 2/20 0.35
GABRD O14764 2/20 0.35
GABRA1 P14867 2/20 0.35
GABRB1 P18505 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28258643 0.90 PTGS1 (0.45) PTGS1PTGS2ALDH1A1HSD17B10ENPEP
SCHEMBL5873778 0.88 PTGS1 (0.47) PTGS1PTGS2ALDH1A1HSD17B10ENPEP
SCHEMBL28406949 0.87 PTGS1 (0.50) PTGS1PTGS2ALDH1A1HSD17B10
SCHEMBL17301050 0.81 PTGS1 (0.46) PTGS1PTGS2CYP1A2ALDH1A1HPGD
SCHEMBL3046367 0.80 CTSD (0.40) CYP1A2ALDH1A1HPGDKDM4EPOLB
SCHEMBL17924909 0.79 MGLL (0.37) PTGS1PTGS2CYP1A2ALDH1A1HPGD
SCHEMBL1535472 0.79 MGLL (0.39) PTGS1PTGS2CYP1A2ALDH1A1HPGD
SCHEMBL1535518 0.78 MGLL (0.46) PTGS1PTGS2CYP1A2ALDH1A1HPGD
SCHEMBL27690608 0.78 ENPEP (0.44) PTGS1PTGS2CYP1A2ALDH1A1HPGD
SCHEMBL29103206 0.78 CYP1A2 (0.33) PTGS1PTGS2CYP1A2POLBCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540172-B2 Therapeutic nanoconjugates comprising Stefin A and uses thereof UNIVERSITAT AUTONOMA DE BARCELONA (UAB) (ES) 2026-02-03 US disclosed
EP-4619417-A1 NANOCONJUGATES CONTAINING PDGFR-BETA LIGANDS AND USES THEREOF Universitat Autònoma de Barcelona (ES) 2025-09-24 EP disclosed
US-12408914-B2 Systems and methods for customizing mechanical strength in stimuli-responsive bioabsorbable materials CILAG GMBH INTERNATIONAL (CH) 2025-09-09 US disclosed
US-20250243250-A1 THERAPEUTIC NANOCONJUGATES AND USES THEREOF UNIV AUTÒNOMA DE BARCELONA UAB (ES) 2025-07-31 US disclosed
EP-4543502-A1 SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS Cilag GmbH International (CH) 2025-04-30 EP disclosed
US-12202866-B2 Therapeutic nanoconjugates and uses thereof UNIVERSITAT AUTONOMA DE BARCELONA (UAB) (ES) 2025-01-21 US disclosed
US-20240423617-A1 SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS CILAG GMBH INTERNATIONAL (CH) 2024-12-26 US disclosed
WO-2024261659-A1 SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS CILAG GMBH INTERNATIONAL (CH) 2024-12-26 WO disclosed
US-20240423620-A1 COMPRESSIBLE SURGICAL ADJUNCTS, CARTRIDGES, AND CARTRIDGE ASSEMBLIES AND METHODS OF MAKING SURGICAL ADJUNCTS CILAG GMBH INTERNATIONAL (CH) 2024-12-26 US disclosed
US-20240382613-A1 METHODS AND SYSTEMS FOR ULTRASOUND STIMULATED STRUCTURES AND DELIVERY OF THERAPEUTIC SPECIES THE PENN STATE RESEARCH FOUNDATION 2024-11-21 US disclosed
EP-3911367-A1 THERAPEUTIC NANOCONJUGATES AND USES THEREOF Universitat Autónoma De Barcelona (UAB) (ES) 2021-11-24 EP disclosed
CN-113597318-A Therapeutic nanoconjugates and uses thereof 巴塞罗那自治大学(UAB) 2021-11-02 CN disclosed
WO-2021130390-A1 SCAFFOLD PROTEINS AND THERAPEUTIC NANOCONJUGATES BASED ON NIDOGEN UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) 2021-07-01 WO disclosed
WO-2020148398-A1 THERAPEUTIC NANOCONJUGATES AND USES THEREOF UNIVERSITAT AUTONOMA DE BARCELONA (UAB) (ES) 2020-07-23 WO disclosed
EP-3651809-A1 THERAPEUTIC NANOCONJUGATES AND USES THEREOF Universitat Autónoma De Barcelona (UAB) (ES) 2020-05-20 EP disclosed
CN-111093718-A Therapeutic nanoconjugates and uses thereof 巴塞罗那自治大学(UAB) 2020-05-01 CN disclosed
WO-2019012157-A1 THERAPEUTIC NANOCONJUGATES AND USES THEREOF UNIVERSITAT AUTÒNOMA DE BARCELONA (UAB) (ES) 2019-01-17 WO disclosed
US-8029979-B2 Method for determining the substrate specificity of an enzyme JPT PEPTIDE TECHNOLOGIES GMBH (DE) 2011-10-04 US disclosed
US-20060234308-A1 Method for determining the substrate specificity of an enzymatic activity and a device therefor JERINI AG (DE) 2006-10-19 US disclosed
US-20040171097-A1 Method for determining the substrate specificity of an enzymatic activity and a device therefor JERINI AG (DE) 2004-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382613-A1 METHODS AND SYSTEMS FOR ULTRASOUND STIMULATED STRUCTURES AND DELIVERY OF THERAPEUTIC SPECIES PAICS, APEX1, ADM2 PTGS1 954/4885PTGS2 837/4885CYP1A2 2582/4885
US-12540172-B2 Therapeutic nanoconjugates comprising Stefin A and uses thereof MYOF, MSTN, NGLY1 PTGS1 4811/4885PTGS2 4831/4885CYP1A2 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.